| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $71,203,579 | 22 | 100 |
| Read Simon | director | 0 | $0 | 2 | $630,786 | $-630,786 |
| McGeorge Anne | director | 0 | $0 | 1 | $844,822 | $-844,822 |
| Soteropoulos Paula | director | 0 | $0 | 3 | $2.25M | $-2.25M |
| Veness Adam M | SVP, General Counsel and Sec. | 0 | $0 | 3 | $4.63M | $-4.63M |
| CARR EDWARD | CHIEF ACCOUNTING OFFICER | 0 | $0 | 2 | $5.59M | $-5.59M |
| Savitz Ryan | CFO & CBO | 0 | $0 | 4 | $14.29M | $-14.29M |
| Randhawa Simrat | EVP, Head of R&D | 0 | $0 | 5 | $15M | $-15M |
| Garcia Marino | CEO AND PRESIDENT | 0 | $0 | 2 | $27.96M | $-27.96M |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell …
Over the last 12 months, insiders at Dianthus Therapeutics, Inc. have bought $0 and sold $71.2M worth of Dianthus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dianthus Therapeutics, Inc. have bought $0 and sold $35.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-17 | Sale | CARR EDWARD | CHIEF ACCOUNTING OFFICER | 20,000 0.0358% | $101.38 | $2.03M | -18.48% | |
| 2026-09-01 | Sale | Randhawa Simrat | EVP, Head of R&D | 23,124 0.0413% | $106.41 | $2.46M | -17.94% | |
| 2026-08-19 | Sale | Read Simon | director | 2,778 0.0051% | $117.55 | $326,554 | -22.32% | |
| 2026-08-10 | Sale | Veness Adam M | SVP, General Counsel and Sec. | 16,167 0.0285% | $110.38 | $1.78M | -15.07% | |
| 2026-08-10 | Sale | Read Simon | director | 2,777 0.0049% | $109.55 | $304,232 | -15.07% | |
| 2026-08-10 | Sale | McGeorge Anne | director | 7,750 0.0135% | $109.01 | $844,822 | -15.07% | |
| 2026-08-07 | Sale | Garcia Marino | CEO AND PRESIDENT | 166,000 0.3946% | $108.11 | $17.95M | -11.43% | |
| 2026-08-07 | Sale | Veness Adam M | SVP, General Counsel and Sec. | 3,833 0.007% | $110.70 | $424,319 | -11.43% | |
| 2026-07-09 | Sale | Savitz Ryan | EVP, CFO & CBO | 31,249 0.0756% | $101.03 | $3.16M | +2.02% | |
| 2026-06-17 | Sale | Veness Adam M | SVP, General Counsel and Sec. | 30,000 0.0709% | $80.80 | $2.42M | +20.28% | |
| 2026-06-01 | Sale | Randhawa Simrat | EVP, Head of R&D | 26,530 0.0644% | $90.62 | $2.4M | +7.45% | |
| 2026-05-08 | Sale | Soteropoulos Paula | director | 599 0.0014% | $85.47 | $51,197 | +7.27% | |
| 2026-04-09 | Sale | Savitz Ryan | EVP, CFO & CBO | 8,224 0.0223% | $89.84 | $738,844 | -1.19% | |
| 2026-03-31 | Sale | Soteropoulos Paula | director | 599 0.0015% | $80.11 | $47,986 | +7.51% | |
| 2026-03-31 | Sale | Savitz Ryan | EVP, CFO & CBO | 114,367 0.2945% | $83.00 | $9.49M | +7.51% | |
| 2026-03-24 | Sale | Soteropoulos Paula | director | 27,594 0.0757% | $78.05 | $2.15M | +14.58% | |
| 2026-03-12 | Sale | Randhawa Simrat | EVP, Head of R&D | 33,830 0.0948% | $81.48 | $2.76M | +11.37% | |
| 2026-03-12 | Sale | Garcia Marino | CEO AND PRESIDENT | 122,918 0.3444% | $81.49 | $10.02M | +11.37% | |
| 2026-03-12 | Sale | CARR EDWARD | CHIEF ACCOUNTING OFFICER | 43,682 0.1224% | $81.49 | $3.56M | +11.37% | |
| 2025-12-04 | Sale | Savitz Ryan | CFO & CBO | 20,000 0.0558% | $45.18 | $903,600 | +90.87% |
| Increased Positions | 122 | +110.91% | 11M | +23.25% |
| Decreased Positions | 46 | -41.82% | 8M | -17.96% |
| New Positions | 47 | New | 2M | New |
| Sold Out Positions | 18 | Sold Out | 3M | Sold Out |
| Total Postitions | 186 | +69.09% | 49M | +5.28% |
| Fmr Llc | $236,915.00 | 13.89% | 5.97M | +1M | +31.39% | 2025-09-30 |
| Fairmount Funds Management Llc | $131,229.00 | 7.69% | 3.31M | +600,000 | +22.16% | 2025-09-30 |
| Avidity Partners Management Lp | $127,142.00 | 7.45% | 3.2M | +1M | +83.84% | 2025-09-30 |
| Ra Capital Management, L.P. | $113,752.00 | 6.67% | 2.87M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $102,282.00 | 6% | 2.58M | +3M | +3,366.88% | 2025-09-30 |
| Octagon Capital Advisors Lp | $95,893.00 | 5.62% | 2.42M | +75,000 | +3.2% | 2025-09-30 |
| Point72 Asset Management, L.P. | $81,025.00 | 4.75% | 2.04M | +649,443 | +46.64% | 2025-09-30 |
| Tcg Crossover Management, Llc | $66,528.00 | 3.9% | 1.68M | +175,000 | +11.65% | 2025-09-30 |
| Vanguard Group Inc | $65,162.00 | 3.82% | 1.64M | +196,117 | +13.56% | 2025-09-30 |
| Blackrock, Inc. | $53,175.00 | 3.12% | 1.34M | -18,690 | -1.38% | 2025-09-30 |